2026-10-01 FDA Warning Letter: Graceful Touch, LLC Cited for Unapproved New Drugs
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs
TL;DR
The short version: On October 1, 2026, the FDA's Center for Drug Evaluation and Research issued a warning letter to Graceful Touch, LLC (Reference 735272) regarding "Herpes B Gone," an unapproved new drug marketed via https://gracefultouchproducts.org/ for treatment of herpes sores and symptoms. The FDA determined the product violates sections 301(d) and 505(a) of the FD&C Act because it is not generally recognized as safe and effective and lacks an approved new drug application, and the agency noted that unapproved STI treatments pose serious public health risks by potentially delaying proper medical care. Graceful Touch was directed to submit a written response within 15 business days outlining corrective actions and prevention measures.
Argus analysis
# FDA Warning Letter Analysis: Graceful Touch, LLC
**Company and Violations**
Graceful Touch, LLC, operated by Guy and Irene Siverson in Rapid City, South Dakota, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on October 1, 2026. The agency identified the product "Herpes B Gone"—marketed through the company's website as a plant-based cream for herpes sores—as an unapproved new drug. The FDA's review in July 2026 determined the product violated federal law by being introduced into interstate commerce without the required approval.
**Regulatory Citations and Context**
The violations center on sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act, along with section 201(g)(1). These provisions establish that any product intended to treat, cure, or mitigate disease qualifies as a drug and requires FDA approval before marketing. Section 201(p) further defines "new drugs" as those not generally recognized as safe and effective (GRASE). The FDA emphasized that no over-the-counter drug has been approved for treating sexually transmitted infections—these require diagnosis and professional medical supervision to prevent serious complications including infertility and sepsis.
**Response Timeline and Monitoring**
Graceful Touch had fifteen business days from receipt to submit a written response to FDAAdvisory@fda.hhs.gov, including corrective actions and preventative measures. Compliance officers in similar industries should monitor whether the company ceases sales, removes product claims, or pursues formal approval pathways. The FDA warning indicates that failure to address violations may result in seizure or injunction. The agency posts warning letters publicly, making this action searchable for customers and healthcare providers evaluating product legitimacy.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Graceful Touch, LLC MARCS-CMS 735272 — October 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Guy Siverson Recipient Title Irene Siverson Graceful Touch, LLC 2040 West Main Street, #209 Rapid City , SD 57702 United States guy@gracefultouch.org irene@gracefultouch.org Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 1, 2026 WARNING LETTER Reference Number: 735272 To Guy and Irene Siverson: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://gracefultouchproducts.org/, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional. FDA Review Violations were identified and documented during a review of your website https://gracefultouchproducts.org/ in July 2026. Based on our review, “Herpes B Gone” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operati…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to Graceful Touch, LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/graceful-touch-llc-735272-10012026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-10-01 FDA Warning Letter: Graceful Touch, LLC Cited for Unapproved New Drugs. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-graceful-touch-llc-2026-10-01-unapproved-drug
"2026-10-01 FDA Warning Letter: Graceful Touch, LLC Cited for Unapproved New Drugs." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-graceful-touch-llc-2026-10-01-unapproved-drug.
Argus HQ Research. "2026-10-01 FDA Warning Letter: Graceful Touch, LLC Cited for Unapproved New Drugs." Digital Empire Holdings LLC. Accessed October 7, 2026. https://argushq.ai/fda/warning-letter/fda-wl-graceful-touch-llc-2026-10-01-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_graceful_touch_llc_2026_10_01_unapproved_drug_2026,
title = {2026-10-01 FDA Warning Letter: Graceful Touch, LLC Cited for Unapproved New Drugs},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-graceful-touch-llc-2026-10-01-unapproved-drug},
note = {Accessed: October 7, 2026}
}